BEFIRADOL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H22ClF2N3O
Molecular Weight	393.858
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC=C(CNCC2(F)CCN(CC2)C(=O)C3=CC=C(F)C(Cl)=C3)N=C1

InChI

InChIKey=PKZXLMVXBZICTF-UHFFFAOYSA-N

InChI=1S/C20H22ClF2N3O/c1-14-2-4-16(25-11-14)12-24-13-20(23)6-8-26(9-7-20)19(27)15-3-5-18(22)17(21)10-15/h2-5,10-11,24H,6-9,12-13H2,1H3

HIDE SMILES / InChI

Molecular Formula	C20H22ClF2N3O
Molecular Weight	393.858
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.prlog.org/12758787-fda-approves-neurolixis-ind-application-for-clinical-trial-with-nlx-112-in-parkinsons-disease.html | http://www.pmlive.com/pharma_news/cancer_pain_opioids_set_to_dominate_602759 | https://adisinsight.springer.com/drugs/800019600 | http://neurolixis.com/images/stories/nlx_pf_license_23sept13.pdf

Befiradol (also known as NLX-112) was initially developed by Pierre Fabre as a selective serotonin-1A receptor agonist for the treatment of cancer pain and neuropathic pain. However, these trials were discontinued. In 2013, the development and commercialization rights were licensed to Neurolixis. Neurolixis studied befiradol in Parkinson’s disease (PD) patients that exhibit dyskinesia. Dyskinesia is a side effect that appears after several years of action Levodopa, a drug that remains the gold standard treatment for PD. In 2019, FDA gave a positive response to Neurolixis’s befiradol to be tested in Phase 2 clinical in Parkinson's disease patients suffering from debilitating levodopa-induced dyskinesia.

Originator

Approval Year

PubMed

Title	Date	PubMed
Novel pyridylmethylamines as highly selective 5-HT(1A) superagonists.	2010-10-14	20860381
[(3)H]-F13640, a novel, selective and high-efficacy serotonin 5-HT(1A) receptor agonist radioligand.	2010-10	20799027
High-efficacy 5-hydroxytryptamine 1A receptor activation counteracts opioid hyperallodynia and affective conditioning.	2006-02	16254131
Conformational analysis and crystal structure of {[1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4yl]methyl}[(5-methylpyridin-2-yl)methyl]amine, fumaric acid salt.	2005-11	16257736
High-efficacy 5-HT1A receptor activation causes a curative-like action on allodynia in rats with spinal cord injury.	2004-08-16	15321732
Tolerance and inverse tolerance to the hyperalgesic and analgesic actions, respectively, of the novel analgesic, F 13640.	2003-04-18	12694810
Profound, non-opioid analgesia produced by the high-efficacy 5-HT(1A) agonist F 13640 in the formalin model of tonic nociceptive pain.	2003-04	12595749

Patents

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:42:34 GMT 2025` Edited by `admin` on `Mon Mar 31 18:42:34 GMT 2025`
Record UNII	RAT9OHA1YH
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BEFIRADOL

Official Name

English

F-13640

Preferred Name

English

Befiradol [WHO-DD]

Common Name

English

(3-CHLORO-4-FLUOROPHENYL)(4-FLUORO-4-((((5-METHYLPYRIDIN-2-YL)METHYL)AMINO)METHYL)PIPERIDIN-1-YL)METHANONE

Systematic Name

English

NLX-112

Code

English

befiradol [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C241